| Metric | Value (₹ Cr) | Q4 FY25 | Q1 FY25 |
|---|---|---|---|
| Revenue | 1.7K | 3.3% | 9.5% |
| Total Income | 1.7K | 3.7% | 9.8% |
| Expenditure | 1.5K | 4.1% | 8.5% |
| PBT | 190.55 | 1.1% | 21.6% |
| Net Profit | 153.63 | 1.9% | 14.2% |
| OPM | 16.45% | 1.08pp | 11.82pp |
| NPM | 8.95% | 0.17pp | 0.37pp |
| EPS | 7.85 | 1.6% | 14.6% |
Alembic Pharmaceuticals Reports Q1 FY26 Profit After Tax at Rs. 154 Cr, Up by 15% 30 June, 2025
05 Aug 2025 · 5 Aug 2025, 01:13 pm
Summary
Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30 June 2025. The company's revenue increased by 10% to Rs.1,711 Cr. EBITDA was up by 20% to Rs. 288 Cr. EBITDA Margin was at 17% of Revenue. Profit Before Tax was up by 21% to Rs.191 Cr. Net Profit was at Rs.154 Cr. up by 15%.
Key Highlights
- 1
India Branded Business delivered a 5% YoY growth, reaching 599 Cr in revenue for the quarter
- 2
US Generics grew by 13% to Rs. 523 Cr. for the quarter
- 3
Ex-US International Generics grew by 21% to Rs. 328 Cr. for the quarter
- 4
API business grew by 1% to Rs. 261 Cr. for the quarter
- 5
4 Launches in the US market during the quarter
- 6
6 ANDA approvals received during the quarter, 223 Cumulative ANDA approvals
Management Comments
Mr. Pranav Amin
we began FY26 on a strong note, delivering revenue growth across all businesses. The growth was driven by a 21% increase in RoW markets, reflecting our strategic expansion and disciplined execution across geographies. Despite ongoing pricing pressure, our US business grew by 13%, supported by volume gains. As we ramp up utilization of our new manufacturing facilities and continue to drive cost optimization initiatives, we expect to benefit from improved operating leverage.
Informational and educational content only. Not investment advice.